Compare APAM & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APAM | AGIO |
|---|---|---|
| Founded | 1994 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | 2011 | 2013 |
| Metric | APAM | AGIO |
|---|---|---|
| Price | $36.18 | $37.39 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $43.00 | $38.88 |
| AVG Volume (30 Days) | 853.5K | ★ 1.2M |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | ★ 10.81% | N/A |
| EPS Growth | ★ 10.66 | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $1,196,688,000.00 | $43,011,000.00 |
| Revenue This Year | $5.96 | $76.75 |
| Revenue Next Year | $5.05 | $170.73 |
| P/E Ratio | $46.59 | ★ N/A |
| Revenue Growth | ★ 7.63 | N/A |
| 52 Week Low | $33.96 | $22.24 |
| 52 Week High | $48.46 | $46.00 |
| Indicator | APAM | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 53.98 | 73.63 |
| Support Level | $35.20 | $36.43 |
| Resistance Level | $38.07 | $43.72 |
| Average True Range (ATR) | 0.95 | 1.49 |
| MACD | 0.07 | 0.32 |
| Stochastic Oscillator | 78.94 | 91.71 |
Artisan Partners Asset Management Inc is a investment management firm providing a range of investment strategies to a diverse group of clients around the world. Each of the company's strategies is managed by one of its several investment teams. Investment management services are offered to institutions through separate accounts and mutual funds. Artisan's investment offerings include several long-only, equity investment strategies across a multitude of market capitalization segments and investing styles in both the United States and international markets. The company operates as one segment in the investment management business. The company generates maximum portion of its revenues from clients domiciled in countries outside the United States.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.